Pröthɛt kanthɛr laa tuɔɔkɛ ɛlɔ̱ŋ kä wutni̱ tin di̱t, kä laa tuɔɔkɛ ɛlɔ̱ŋ kä wutni̱ tin di̱t ni̱ kɛn kä run 65.
Ɛ nyɔk bä, wutni̱ tin te kɛ ji̱ gɔaal ti̱ ci̱ kɔn tekɛ kanthɛr pröthɛt te kɛ riɛk mi̱ di̱i̱t, ce̱tkɛ wutni̱ ji̱ Africa kä America kɛnɛ wutni̱ tin bä kä Caribbean.
Nɛmɛ derɛ tuɔɔk kɛ kui̱i̱ ji̱i̱n mi̱ ci̱ rɔ gɛr min bi̱ ben ɛ la mi̱ di̱i̱t ɛlɔ̱ŋ kä tin laa jakɛ pieth ran kä bɛ rɔ rep kiɛ mi̱ /ci̱ ji̱i̱n in laa luäŋ kɛ luäŋ kɛ pieth ran rɔ rep.
Kɛn mutɛciɔni̱ ti̱ti̱ dëë kɛ jakä bi̱ kɛ rɔ̱ rep ɛ /ci̱ mɔ a min görkɛ, kä bi̱ kɛ cu nööŋni̱ ta̱a̱ in bi̱ tuɔmɔr rɔ̱ rep.
Mi̱ ci̱ tuɔmɛr piith, derɛ puɔ̱ny kɛnɛ cuŋ pua̱a̱ny tin thia̱k kɛ jɛ ben käp, ce̱tkɛ min cie puɔ̱ny mi̱ di̱i̱t, puɔ̱ny mi̱ di̱i̱t, kɛnɛ puɔ̱ny mi̱ thia̱k kɛ jɛ.
Kɛ tha̱a̱ŋ gua̱thni̱, thëlli̱ kanthɛr derɛ rɔ̱ woc kä tuɔmɛr in nhiam kä derɛ rɔ̱ däk kä tha̱a̱ŋ pua̱a̱ny kɛ riɛm kiɛ thi̱thtɛm limpatik, ɛ la̱t mi̱ cɔali̱ metɛthta̱thith.
Mi ci kanthɛr rɔ däk, bɛ cu bɛc ɛlɔ̱ŋ kɛ ɣöö ba jɛ ciɛŋ.
Pröthɛt kanthɛr bä derɛ te kɛ luäŋ kɛ ɣörmönal pa̱kciɛri̱, cie min te kä ɣörmön andröjen ɣörmön tɛthtöthtɔrön.
Tethtɔthtɔrɔɔn derɛ pieth thëlli̱ pröthɛt kanthɛr jakä di̱t, kä ciɛŋ ti̱ ŋuan kɛ kui̱ pröthɛt kanthɛr görkɛ ɣöö ba pek ɣɔrmɔɔn ɛmɛ jakä kuiy kiɛ bi̱ lätkɛ cu te thi̱n.
Kɛ thuɔ̱kdɛ, ɛn pato̱thi̱ji̱ölöji̱ pröthɛt kancer matdɛ ni̱ pieth kɛnɛ dääk thëlli̱ tin /ca luäŋ kɛ ga̱ŋ rɛy pröthɛt gland, min de ben ɛ ji̱i̱n, ɣörmɔɔnal, kɛnɛ gua̱th in cieŋ raan thi̱n.
Ŋäc in te piny jua̱th ɛ mi̱ di̱i̱t ɛlɔ̱ŋ kɛ kui̱ kä ɣöö ba ka̱m raar kɛ luäk mi̱ gɔaa kɛnɛ ɣöö ba ji̱ jua̱th tin tekɛ kanthɛr pröthɛt jakä gɔaa.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Lät kɛ kui̱i̱ jua̱thni̱']
['Ɛn wɛbthaay ɛmɛ ca la̱th lät kɛ kui̱ ŋi̱i̱cä kɛnɛ läri kä /cɛ lot ni ɣöö ba ji̱ moc kɛ luäk ki̱mä kiɛ lät ti̱ gööl.']
['Lät kɛ läri tin ca ŋun /ca kɛ bi̱ lät kɛ ɣöö ba jua̱th jek kiɛ ba kɛ ciɛŋ, kä nɛy tin görkɛ luäk ki̱mädiɛn kärɔ̱ ba kɛ thiec kä ki̱m mi̱ tekɛ luäk ki̱mä.']
['Guic ɛ gɔaa ɛn ɣöö ɛn neural net min jak luɔc kä thie̱cni̱, /cɛ thuɔ̱k ɛlɔ̱ŋ mi̱ ci̱ ben kä nämbäri̱ tin te thi̱n. cetkɛ pek nath tin ca jek kɛ juey mi̱ rɛlrɔ.']
['Ni ciaŋ go̱ri ruac kä ki̱mdu kiɛ ram in kɔ̱ŋ mi ŋäc luäk pua̱a̱ny kɛ kui̱ jua̱thdu. /Cu ruac ki̱mdu car kiɛ jääny kɛ go̱ri kɛ kui̱ kä mi ci kuɛn kä wɛbthaay ɛmɛ. Mi caari jɛ ɛn ɣöö deri tekɛ juey mi go̱o̱ri luäk, cɔl 911 kiɛ wër guäth in thia̱k kɛ ji kɛ pɛ̈th. /Thilɛ maar kam ki̱m kɛnɛ juey mi bi̱ tuɔɔk kɛ kui̱ kä wɛbthaay ɛmɛ kiɛ la̱tdɛ. /Ci̱ BioMedLib kiɛ la̱a̱tkɛ, kiɛ ram in gɔ̱a̱r kɛ kui̱ kä wɛbthaay ɛmɛ, bi̱ ruac lat, kiɛ bi̱ ruac lat, kɛ kui̱ läri tin ca ka̱m raar rɛydɛ kiɛ la̱tdɛ.']
['Lät kɛ: ŋuɔ̱t']
['Ɛn Digital Millennium Copyright Act 1998, 17 U.S.C. § 512 (ɛ DMCA) ɛ ŋuɔ̱t mi̱ ŋun ji̱ cuŋni̱ tin ŋääth kɛn ɣöö ci̱ ŋɔaani̱ tin te kä intɛrnɛt ŋuɔ̱tkiɛn to̱l kɛ kui̱ ŋuɔ̱tni̱ cuŋni̱ tin te kä U.S.']
['Mi ca ji̱ ŋäth kɛ thuɔ̱k ɛn ɣöö tëëkɛ mi̱ ca gɔ̱r kiɛ mi̱ ca ka̱m ji̱ rɛy wɛbthaayäda kiɛ lät tin kɔ̱ŋ tin ci̱ ŋuɔ̱t tin ca gɔ̱r ya̱r, ji̱n (kiɛ ram in lät kɛ kui̱du) deri̱ kɔ jäk kä warɛgak mi̱ bi̱ ji̱ thiec ɛn ɣöö ba min ca gɔ̱r kiɛ min ca gɔ̱r woc, kiɛ ba duɔ̱ɔ̱r la̱t kɛ ɣöö bi̱ ji̱ cop thi̱n.']
['Kɛn läri̱ ba kɛ jäk kɛ wargak ɛ la i̱thtäm (guic ni̱ gua̱th in ci̱ i̱thtäm in ca gɔ̱r "Kɔntak" kɛ kui̱ i̱thtäm in ci̱ jäk).']
['DMCA go̱o̱rɛ ɣöö bi̱ ji̱n warɛgakdu lat kɛ kui̱ kä tin ca lar i̱ ci̱ ŋuɔ̱t gɛr kɛ kui̱i̱ ŋuɔ̱tni̱ gɔ̱rä mat thi̱n kɛ läär ti̱ti̱: (1) latdɛ kɛ kui̱i̱ la̱t in ca gɛr kɛ kui̱i̱ ŋuɔ̱tni̱ gɔ̱rä min ca lar i̱ ca gɛr; (2) latdɛ kɛ kui̱i̱ kä tin ca lar i̱ ci̱ ŋuɔ̱t gɛr kɛnɛ läär ti̱ ro̱ŋ kɛ ɣöö bi̱ kɔn kɛ jek; (3) läri̱ kɛ kui̱i̱ kä min dëë ji̱ luäk kɛ jek, amäni̱ ci̱ötdu, nämbärɛ kä tin ci̱ ji̱ luäk kɛ jek, kɛnɛ emaildu; (4) latdu kɛ ɣöö ci̱ ji̱n ɛ ŋa̱c ɛn ɣöö min ca gɔ̱r kɛ kui̱i̱ kä tin ca lar /ci̱kɛ bi̱ lät kɛ luäkdɛ ɛ gua̱n ŋuɔ̱tni̱ gɔ̱rä, kiɛ ɛ la̱tdɛ, kiɛ kɛ luäk ŋuɔ̱tni̱; ']
['(5) mi ci ji gɔr piny kɛ kuic kä ɣöö bi ji ruac kɛ thuɔ̱k, ɛn ɣöö läri tin ca gɔr ɛ thuɔ̱k kä te ji kɛ lua̱ŋ kɛ ɣöö bi yiöw tin ca gɔr piny tin ca lar ɛ ji̱n ka̱m raar;']
['kɛnɛ (6) mi̱ ca gɔ̱r piny ɛ gua̱n ŋuɔ̱tni̱ kiɛ ram mi̱ tekɛ lua̱ŋ kɛ lät kɛ kui̱dɛ.']
['Mi /kenɛ läri tin ca lat nhial diaal mat thi̱n dɔ̱ŋ derɛ ku lɛ wɔ̱ jɔ̱ɔ̱r kɛ lätni̱ kɛ kɛ.']
['Röm kɛ jɛ']
['Thiecɛ kɔ kɛ email kɛ thiecni kiɛ cär.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Kɛ kui̱']
['BiöMedLib lät kɛ kɔmpi̱e̱tɛri̱ tin lät kärɔ̱ (algorithmi̱ni̱ tin ŋi̱e̱e̱e̱c kɛ makanɛ) kɛ ɣöö ba thie̱e̱cni̱ kɛnɛ luɔcdiɛn kulɛ jiek.']
['Kɔn cua tok kɛ mi̱lli̱ön 35 kä baömedikal publi̱kecin PubMed/Medline. Kä bä, webpage duŋ RefinedWeb.']
